(2,2-二甲基-1-氧代丙氧基)丁酸甲酯
| 中文名称 | (2,2-二甲基-1-氧代丙氧基)丁酸甲酯 |
|---|---|
| 中文同义词 | 化合物 T16545;新戊酰基氧基甲基丁酸酯;(2,2-二甲基-1-氧代丙氧基)丁酸甲酯;化合物PIVANEX |
| 英文名称 | pivalyloxymethyl butyrate |
| 英文同义词 | pivalyloxymethyl butyrate;((2,2-Dimethylpropanoyl)oxy)methyl butanoate;Brn 4861411;Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester;Pivanex;Chronic,leukemia,AN 9,muscular,Acute,ALL,atrophy,Inhibitor,lung,Histone deacetylases,NSCLC,myelogenous,lymphoblastic,cancer,HDAC,AN9,CML,Pivanex,spinal,K562,Apoptosis,inhibit,Bcr-Abl |
| CAS号 | 122110-53-6 |
| 分子式 | C10H18O4 |
| 分子量 | 202.25 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 122110-53-6.mol |
| 结构式 |  |
(2,2-二甲基-1-氧代丙氧基)丁酸甲酯 性质
| 沸点 | 249.3±13.0 °C(Predicted) |
|---|---|
| 密度 | 1.008±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 二甲基亚砜：≥10mg/mL |
| 形态 | 油状 |
| 颜色 | 无色或微黄色 |
|
HDAC
|
Bcr-Abl
|
Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.
Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.
Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.
Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Cell Viability Assay
| Cell Line: | K562 cells. |
| Concentration: | 100-500 μM. |
| Incubation Time: | 24 hours. |
| Result: |
Reduced the number of K562 viable cells significantly.
100 μM Pivanex with 0.125 or 0.25 μM STI571 reduced the number of viable cells synergistically. |
Apoptosis Analysis
| Cell Line: | K562 cells. |
| Concentration: | 100-500 μM. |
| Incubation Time: | 6-72 hours. |
| Result: |
Increased the number of K562 apoptotic cells significantly.
Increased the caspase activity in K562 cells significantly after only 4 h of incubation with 500 μM. |
Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss.
| Animal Model: | SMN7 SMA mice (SMN2 +/+ ; SMN7 +/+ ; mSmn −/− ). |
| Dosage: | 200 mg/kg. |
| Administration: | Oral administration, b.i.d, at 09.00 and 17.00 daily. |
| Result: |
Improved the mean lifespan of treated SMN7 SMA mice by 84.6%.
Delayed the onset of body mass loss in SMN7 SMA mice by 94.9%. |
安全信息
| WGK Germany | nwg |
|---|